Jon Rampton
Family Medicine · Moberly, MONPI 1548269079
Payments from drug & device makers
Across 799 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$892
- Pfizer$538
- plus $4K from 43 others
What the payments were for
- Food & beverage$12,006100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,020 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 200 | $149,233 |
| OzempicSemaglutide | 108 | $102,627 |
| JardianceEmpagliflozin | 97 | $83,826 |
| EliquisApixaban | 95 | $82,246 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $56,648 |
| TrulicityDulaglutide | 47 | $52,700 |
| MounjaroTirzepatide | 45 | $47,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $40,597 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $38,244 |
| XareltoRivaroxaban | 73 | $36,908 |
| JanuviaSitagliptin Phosphate | 48 | $36,557 |
| LinzessLinaclotide | 52 | $35,428 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $27,262 |
| InvokanaCanagliflozin | 29 | $19,394 |
| VraylarCariprazine Hcl | 13 | $18,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort, Brilinta | $2,023 | $216,445333 claims |
| Novo NordiskOzempic, Rybelsus | $1,287 | $121,328119 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Glyxambi, Tradjenta | $294 | $112,941149 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,393 | $100,07392 claims |
| PfizerEliquis | $538 | $82,24695 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $217 | $68,47591 claims |
| Johnson & JohnsonXarelto, Invokana | $224 | $56,302102 claims |
| AbbVieLinzess, Vraylar | $1,410 | $54,28365 claims |
| MerckJanuvia, Belsomra | $279 | $52,34176 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $18,73224 claims |
| NovartisEntresto | $216 | $13,26520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Moberly
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.